HIV Treatment Bulletin - Vol. 6, No. 1, December 2004 / January 2005
Graham McKerrow, HIV i-Base

Pravastatin improves the dyslipidaemia of HIV-positive people on ART but this does not translate to improved endothelial function (EF). Persistently elevated C-reactive protein (CRP) values suggest that there may be an ongoing stimulus towards cardiovascular (CV) risk that has yet to be elucidated, Sklar and colleagues in the United States conclude from a randomised, placebo-controlled, crossover study.

Twenty-three HIV-positive patients on stable ART completed the study to evaluate the effect of pravastatin (40mg) on endothelial function, which was assessed by flow-mediated vasodilation of the brachial artery.

At baseline, HIV-positive individuals demonstrated abnormal EF compared with an otherwise healthy, HIV-negative population (mean ± SEM, 7.0±0.5% HIV vs. 10.1±0.9 controls, p=0.002). Active treatment with pravastatin significantly reduced total cholesterol (mean -36±5 mg/dL, p<.001), LDL-cholesterol (-30±4, p<.001), and triglycerides (-69±25, p=.01). There was no effect on HDL-cholesterol or measures of insulin resistance.

Despite the overall improvement in metabolic risk profiles, pravastatin showed no consistent or significant improvement in EF (mean 7.0% on drug, 7.3% on placebo, P=0.68). CRP values were similarly unaffected (mean 6.3 on drug, 6.7 on placebo, p=0.85); there was no significant correlation between FMD and CRP at baseline (correlation coefficient = -0.16, p=0.45)

Ref: Sklar PA, Grubb JR, Voell JD et al. Endothelial dysfunction in HIV-infected patients on CART does not improve even when lipid profiles improve on pravastatin. Antiviral Therapy 2004; 9:L15 Abstract 24.

041210
IB050601-12

©2004. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone / Firestone Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.